Starting from a deep understanding of molecular immunology, we employ our SEQ SIFTER™ antibody-based therapeutic discovery platform to potentially enable faster, deeper and more sustained clinical responses. We push the limits of single-cell genomic technology to capture and analyze very rare human B cells expressing allergen binding antibodies. We engineer these antibodies to uniquely capture allergens and endow them with powerful immune modulating activities derived from the IgG antibody class to suppress allergic reactions. Our team is at work today to make this new life changing therapy tomorrow’s reality.